Tamtam Try Tamtam free
Alkermes logo

Alkermes account plan

Developing medicines for neurological disorders

At a glance

Alkermes is an Ireland-headquartered neuroscience biopharma selling psychiatry, addiction and sleep medicines in the U.S., with about 2,050 employees.

Alkermes plc is a neuroscience biopharmaceutical company headquartered in Dublin, Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing plant in Wilmington, Ohio. It sells VIVITROL (addiction), ARISTADA and LYBALVI (schizophrenia and bipolar I disorder) and, since the Avadel acquisition of February 12, 2026, LUMRYZ (narcolepsy) in the U.S., and earns manufacturing and royalty revenues on Janssen's long-acting INVEGA products, RISPERDAL CONSTA and Biogen's VUMERITY. FY2025 total revenues were $1,475,899 thousand and net income from continuing operations $241.7 million (vs $372.1 million in 2024). It had approximately 2,050 full-time employees as of February 20, 2026, about 1,950 of them in the U.S. The company is managed as one segment; Blair Jackson became Chief Executive Officer in 2026, succeeding Richard Pops.

Business units

Strategic priorities

Execution under a new CEO
Blair Jackson's first quarterly call (November 3, 2026) named three priorities: advancing the pipeline with rigor and urgency, driving strong commercial and financial performance, and allocating capital thoughtfully.
Orexin 2 receptor agonist pipeline
Alixorexton is in phase 3 Brilliance studies in NT1 and NT2, with topline results beginning in mid-2027, and in phase 2 Vibrance-3 in idiopathic hypersomnia. About six medium- or late-stage programs report over the next 12 months, per the CEO in November 2026.
Leadership in sleep medicine
LUMRYZ and its narcolepsy commercial organisation are meant to support the potential launch of alixorexton. Positive phase 3 REVITALYZ data in idiopathic hypersomnia (May 2026) support an sNDA with a potential launch in March 2028.
Expansion beyond sleep
ALKS 7290 showed positive phase 1 ADHD data (September 21, 2026) and is in phase 2 in ADHD (data in the second half of 2027) and a 150-patient phase 2 in MDD. ALKS 4510 is planned for a phase 2 in fatigue associated with MS or Parkinson's disease.
Grow the proprietary portfolio
Management expects proprietary product net sales of nearly $1.6 billion in 2026, with LYBALVI prescription volume growing nearly 20% in 2027 after its access expansion.

Latest results

In Q3 2026 (quarter to September 30, 2026), total revenues were $480,132 thousand against $394,185 thousand a year earlier, and proprietary net sales rose 31% to $417.3 million, primarily due to the addition of LUMRYZ. Net income fell to $16.3 million from $82.8 million, and the first nine months show a net loss of $49.7 million, driven by Avadel deal costs, the $121.6 million LUMRYZ inventory step-up, intangible amortization and $27.6 million of quarterly interest expense. Adjusted EBITDA was $120.1 million and cash and investments $787.6 million. Management reiterated 2026 guidance across all line items, with Q4 proprietary sales of $400-420 million; for 2027 it expects lower cost of goods, broadly similar SG&A and higher R&D, with full guidance in February.

Investments and deals

Avadel acquisition
Completed February 12, 2026 for $21.00 per Avadel share in cash plus a CVR of up to $1.50; cash consideration paid at closing was $2,199.2 million. It added LUMRYZ and a narcolepsy sales force of approximately 60 people.
Acquisition financing
A $1.525 billion senior secured term loan A and B package replaced the bridge facility; after the August 12, 2026 amendment the TLA stands at up to $745.3 million and the TLB at up to $773.1 million, both due 2031.
Rising R&D spend
R&D rose to $324.0 million in FY2025 (from $245.3 million) and to $121.1 million in Q3 2026 (vs $81.7 million), with R&D headcount up 16% in the quarter; R&D expense is expected to increase again in 2027.
Capital expenditure
Capex is guided at approximately $40.0 million to $50.0 million for 2026.
Share buybacks
About 1.0 million shares were repurchased in Q1 2026 for $27.7 million; $172.3 million remains authorised under the $400.0 million program.

Challenges and risks

VIVITROL generic entry
The company expects generic versions of VIVITROL, its largest product, to enter the market in 2027; Teva and Amneal hold settlement licences.
Patent litigation and royalty expiries
Paragraph IV litigation is under way on LYBALVI patents expiring between 2032 and 2041, and the expiry of the U.S. INVEGA SUSTENNA royalty cut long-acting INVEGA revenues to $109.6 million in FY2025 from $236.5 million.
Orexin competition
Takeda is launching the first orexin agonist for NT1, and Lilly is investing behind its Centessa acquisition; alixorexton must differentiate on efficacy and dosing flexibility.
Acquisition debt and integration
The 10-K flags failure to realise Avadel synergies and new secured debt with covenants as risks; nine-month 2026 operating cash flow fell to $72.9 million from $350.6 million.
U.S. pricing and controlled-substance rules
Gross-to-net deductions were 47.7% in Q3 2026 under Medicaid, 340B and Medicare Part D pressure, and LUMRYZ is a DEA-controlled substance under a REMS, made by contract manufacturers.

What leadership says

“We have a clear strategy and a strong foundation. Our focus now is on execution.”

Blair Jackson, Chief Executive Officer · Alkermes Q3 2026 earnings call, November 3, 2026

“the next year will be a pivotal and data-rich period for Alkermes, with six important studies expected to read out across our orexin portfolio.”

Blair Jackson, Chief Executive Officer · Alkermes Q3 2026 earnings call, November 3, 2026

“We have generated over $1.8 billion of revenue this year. We are highly profitable.”

Blair Jackson, Chief Executive Officer · Stifel 2026 Healthcare Conference, November 10, 2026

“We are a profitable neuroscience company with a late-stage candidate and leadership in an exciting new therapeutic category.”

Richard Pops, then Chief Executive Officer · 44th Annual J.P. Morgan Healthcare Conference, January 13, 2026

Where a supplier can help

Clinical trial operations
Six orexin readouts in the next year, three phase 3 Brilliance studies and new phase 2 studies in ADHD, MDD and fatigue create demand for site management, patient recruitment and trial data services.
Sleep-medicine commercial launch support
The goal of leadership in sleep medicine, the LUMRYZ IH sNDA and a potential alixorexton launch call for HCP targeting, market access and field-force tools for the narcolepsy organisation.
Integration and finance tooling
Integrating Avadel, servicing term loans with covenants and an 18% rise in sales and marketing headcount point to needs in finance, HR and CRM integration.
Gross-to-net and market access analytics
Gross-to-net deductions near 47.7% and Medicare Part D pressure on LYBALVI make rebate management, contracting and pricing analytics a direct lever on net sales.
Manufacturing quality and supply
Out-of-specification batch costs on ARISTADA and VIVITROL, reliance on contract manufacturers for LUMRYZ and DEA quotas open room for quality, supply-chain and compliance suppliers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Alkermes?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Alkermes

What does Alkermes do?

Alkermes develops and sells neuroscience medicines in the U.S.: VIVITROL for addiction, ARISTADA and LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for narcolepsy. It also earns royalties and manufacturing revenue on products licensed to Janssen and Biogen.

What is Alkermes' revenue?

FY2025 total revenues were $1,475,899 thousand. In Q3 2026 revenues were $480,132 thousand, and the proprietary portfolio is expected to deliver nearly $1.6 billion of net sales in 2026.

How many employees does Alkermes have?

Approximately 2,050 full-time employees as of February 20, 2026, about 1,950 in the U.S. and about 100 in Ireland.

Who leads Alkermes?

Blair Jackson is Chief Executive Officer; November 3, 2026 was his first quarterly call in the role. Richard Pops was Chairman and Chief Executive Officer at the time of the FY2025 10-K.

What is Alkermes' strategy?

It uses its profitable commercial business to fund orexin 2 receptor agonist research, led by alixorexton in narcolepsy and IH, and aims to become a leader in sleep medicine through LUMRYZ.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)